{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:31:40Z","timestamp":1793039500337,"version":"4.5.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.medcli.2025.107184","type":"journal-article","created":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T13:59:49Z","timestamp":1758981589000},"page":"107184","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efectos de los f\u00e1rmacos con acci\u00f3n GLP-1 sobre las comorbilidades o enfermedades relacionadas con obesidad"],"prefix":"10.1016","volume":"165","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3188-1990","authenticated-orcid":false,"given":"Nuria","family":"Vilarrasa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9510-7251","authenticated-orcid":false,"given":"Silvia","family":"Pellitero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medcli.2025.107184_bib0220","doi-asserted-by":"crossref","first-page":"89","DOI":"10.5665\/sleep.1592","article-title":"Interrelationships between body mass, oxygen desaturation, and apnea-hypopnea indices in a sleep clinic population","volume":"35","author":"Ling","year":"2012","journal-title":"Sleep"},{"key":"10.1016\/j.medcli.2025.107184_bib0225","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1152\/japplphysiol.00587.2005","article-title":"Excess weight and sleep-disordered breathing","volume":"99","author":"Young","year":"2005","journal-title":"J Appl Physiol (1985)"},{"key":"10.1016\/j.medcli.2025.107184_bib0230","first-page":"430","volume":"108","author":"Schwartz","year":"2010","journal-title":"Obesity and upper airway control during sleep. J Appl Physiol (1985)"},{"key":"10.1016\/j.medcli.2025.107184_bib0235","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1093\/sleep\/32.12.1579","article-title":"Abdominal compression increases upper airway collapsibility during sleep in obese male obstructive sleep apnea patients","volume":"32","author":"Stadler","year":"2009","journal-title":"Sleep"},{"key":"10.1016\/j.medcli.2025.107184_bib0240","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.5664\/jcsm.9834","article-title":"Dose-response relationship between weight loss and improvements in obstructive sleep apnea severity after a diet\/lifestyle interventions: secondary analyses of the \u201cMIMOSA\u201d randomized clinical trial","volume":"18","author":"Georgoulis","year":"2022","journal-title":"J Clin Sleep Med"},{"key":"10.1016\/j.medcli.2025.107184_bib0245","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1001\/archinternmed.2009.266","article-title":"A randomized study on the effect of weight loss on obstructive sleep apnea among obese patients with type 2 diabetes: the Sleep AHEAD study","volume":"169","author":"Foster","year":"2009","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.medcli.2025.107184_bib0250","first-page":"104","volume":"19","author":"Strobel","year":"1996","journal-title":"Obesity and weight loss in obstructive sleep apnea: a critical review Sleep"},{"key":"10.1016\/j.medcli.2025.107184_bib0255","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.3390\/jcm10071485","article-title":"Body Mass Index Reduction and Selected Cardiometabolic Risk Factors in Obstructive Sleep Apnea: Meta-Analysis","volume":"10","author":"Stelmach-Mardas","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.medcli.2025.107184_bib0260","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.diabet.2014.10.005","article-title":"Liraglutide treatment in a patient with HIV, type 2 diabetes and sleep apnoea-hypopnoea syndrome","volume":"41","author":"Garc\u00eda de Lucas","year":"2015","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.medcli.2025.107184_bib0265","first-page":"86","article-title":"Effects of liraglutide on sleep-disordered breathing and diabetic microangiopathy in patients with type 2 diabetes mellitus and obstructive sleep apnea-hypopnea syndrome","volume":"12","author":"Liu","year":"2020","journal-title":"Chin J Diabetes Mellit"},{"key":"10.1016\/j.medcli.2025.107184_bib0270","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1513\/AnnalsATS.202309-821OC","article-title":"Continuous Positive Airway Pressure but Not GLP1-mediated Weight Loss Improves Early Cardiovascular Disease in Obstructive Sleep Apnea: A Randomized Proof-of-Concept Study","volume":"21","author":"O\u2019Donnell","year":"2024","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.medcli.2025.107184_bib0275","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/j.1365-2869.2012.01030.x","article-title":"Exenatide improves excessive daytime sleepiness and wakefulness in obese patients with type 2 diabetes without obstructive sleep apnoea","volume":"22","author":"Idris","year":"2013","journal-title":"J Sleep Res"},{"key":"10.1016\/j.medcli.2025.107184_bib0280","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12902-015-0074-6","article-title":"An association between liraglutide treatment and reduction in excessive daytime sleepiness in obese subjects with type 2 diabetes","volume":"15","author":"Gomez-Peralta","year":"2015","journal-title":"BMC Endocr Disord"},{"key":"10.1016\/j.medcli.2025.107184_bib0285","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1007\/s11325-022-02768-y","article-title":"Efficacy and safety of liraglutide in patients with type 2 diabetes mellitus and severe obstructive sleep apnea","volume":"27","author":"Jiang","year":"2023","journal-title":"Sleep Breath"},{"key":"10.1016\/j.medcli.2025.107184_bib0290","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/ijo.2016.52","article-title":"Effect of liraglutide 3.0mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial","volume":"40","author":"Blackman","year":"2016","journal-title":"Int J Obes (Lond)"},{"key":"10.1016\/j.medcli.2025.107184_bib0295","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1056\/NEJMoa2404881","article-title":"Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity","volume":"391","author":"Malhotra","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2025.107184_bib0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.155937","article-title":"Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease?","volume":"157","author":"Huttasch","year":"2024","journal-title":"Metabolism"},{"key":"10.1016\/j.medcli.2025.107184_bib0305","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.2337\/dci24-0003","article-title":"Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity","volume":"47","author":"Drucker","year":"2024","journal-title":"Diabetes Care"},{"key":"10.1016\/j.medcli.2025.107184_bib0310","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1016\/j.cell.2024.06.003","article-title":"Transforming obesity: The advancement of multi-receptor drugs","volume":"187","author":"Kusminski","year":"2024","journal-title":"Cell."},{"key":"10.1016\/j.medcli.2025.107184_bib0315","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.medcli.2025.107184_bib0320","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2025.107184_bib0325","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S2468-1253(23)00068-7","article-title":"Semaglutide 24mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial","volume":"8","author":"Loomba","year":"2023","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"10.1016\/j.medcli.2025.107184_bib0330","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medcli.2025.107184_bib0335","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S2213-8587(22)00070-5","article-title":"Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial","volume":"10","author":"Gastaldelli","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.medcli.2025.107184_bib0340","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2025.107184_bib0345","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1016\/j.cgh.2024.04.017","article-title":"Safety and Efficacy of Novel Incretin Co-agonist Cotadutide in Biopsy-proven Noncirrhotic EHNA With Fibrosis","volume":"22","author":"Shankar","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.medcli.2025.107184_bib0350","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa2401755","article-title":"A Phase 2 Randomized Trial of Survodutide in EHNA and Fibrosis","volume":"391","author":"Sanyal","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2025.107184_bib0355","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jhep.2024.07.006","article-title":"Effect of pemvidutide, a GLP-1\/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study","volume":"82","author":"Harrison","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.medcli.2025.107184_bib0360","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.jhep.2023.05.013","article-title":"A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease","volume":"79","author":"Romero-G\u00f3mez","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.medcli.2025.107184_bib0365","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2025.107184_bib0370","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1038\/s41591-024-03015-5","article-title":"Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial","volume":"30","author":"Colhoun","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.medcli.2025.107184_bib0375","doi-asserted-by":"crossref","first-page":"4457","DOI":"10.3390\/ijms23084457","article-title":"Psoriasis and Systemic Inflammatory Disorders","volume":"23","author":"Tashiro","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.medcli.2025.107184_bib0380","article-title":"The Pathogenesis and Treatment of Hidradenitis Suppurativa","volume":"15","author":"Agnese","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.medcli.2025.107184_bib0385","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1111\/j.1468-3083.2012.04609.x","article-title":"Glucagon-like peptide-1 analogue therapy for psoriasis patients with obesity and type 2 diabetes: a prospective cohort study","volume":"27","author":"Ahern","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.medcli.2025.107184_bib0390","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1007\/s00125-011-2232-3","article-title":"Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis","volume":"54","author":"Hogan","year":"2011","journal-title":"Diabetologia"},{"key":"10.1016\/j.medcli.2025.107184_bib0395","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/bjd.12886","article-title":"Improvement of psoriasis during glucagon-like peptide-1 analogue therapy in type 2 diabetes is associated with decreasing dermal \u03b3\u03b4 T-cell number: a prospective case-series study","volume":"171","author":"Buysschaert","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.medcli.2025.107184_bib0400","doi-asserted-by":"crossref","DOI":"10.1530\/EDM-21-0007","article-title":"Two birds one stone: semaglutide is highly effective against severe psoriasis in a type 2 diabetic patient","author":"Costanzo","year":"2021","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"10.1016\/j.medcli.2025.107184_bib0405","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/jdv.12629","article-title":"Lack of effect of the glucagon-like peptide-1 receptor agonist liraglutide on psoriasis in glucose-tolerant patients--a randomized placebo-controlled trial","volume":"29","author":"Faurschou","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.medcli.2025.107184_bib0410","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1159\/000473873","article-title":"A Disease-Modifying Approach for Advanced Hidradenitis Suppurativa (Regimen with Metformin, Liraglutide, Dapsone, and Finasteride): A Case Report","volume":"9","author":"Khandalavala","year":"2017","journal-title":"Case Rep Dermatol"},{"key":"10.1016\/j.medcli.2025.107184_bib0415","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.medcli.2023.11.007","article-title":"Liraglutide for the treatment of obesity among patients with hidradenitis suppurativa","volume":"162","author":"Nicolau","year":"2024","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.medcli.2025.107184_bib0420","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1093\/bjd\/ljae216","article-title":"Semaglutide for weight loss in people with obesity as an adjunctive treatment for hidradenitis suppurativa: its impact on disease control and quality of life","volume":"191","author":"Lyons","year":"2024","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.medcli.2025.107184_bib0425","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1007\/s00125-011-2297-z","article-title":"Glucagon-like peptide-1 (GLP-1) receptor agonists, obesity and psoriasis: diabetes meets dermatology","volume":"54","author":"Drucker","year":"2011","journal-title":"Diabetologia"},{"key":"10.1016\/j.medcli.2025.107184_bib0430","doi-asserted-by":"crossref","first-page":"6292","DOI":"10.3390\/jcm13216292","article-title":"The Therapeutic Potential of GLP-1 Receptor Agonists in the Management of Hidradenitis Suppurativa: A Systematic Review of Anti-Inflammatory and Metabolic Effects","volume":"13","author":"Krajewski","year":"2024","journal-title":"J Clin Med"}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775325004129?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775325004129?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T13:44:14Z","timestamp":1771508654000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775325004129"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S0025775325004129"],"URL":"https:\/\/doi.org\/10.1016\/j.medcli.2025.107184","relation":{},"ISSN":["0025-7753"],"issn-type":[{"value":"0025-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efectos de los f\u00e1rmacos con acci\u00f3n GLP-1 sobre las comorbilidades o enfermedades relacionadas con obesidad","name":"articletitle","label":"Article Title"},{"value":"Medicina Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medcli.2025.107184","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107184"}}